Follow-On Biologic Stakeholders Agree On Patent Resolution, Differ On Details
• By Cathy Dombrowski
Inclusion of a mechanism for patent dispute resolution in the pathway for approving follow-on biologics was supported by representatives on both sides of the FOB debate during a Federal Trade Commission workshop Nov. 21
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
